LIPOSYN 10%
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
May 1979
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 21h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LIPOSYN 10% is an intravenous lipid emulsion approved in 1979 for parenteral nutrition support. The product delivers essential fatty acids and calories to patients unable to meet nutritional needs orally or enterally. It is a small-molecule lipid formulation administered by injection.
LOE Approaching
As LOE approaches with moderate competitive pressure (30), the brand team is likely consolidating focus on retention and cost management rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
This product offers limited new career growth opportunities given its LOE-approaching status and minimal linked job openings. Professionals joining this brand should expect focus on defending market position, managing reimbursement challenges, and supporting hospital/institutional contracts rather than launching new initiatives.
Brand ManagerAccount Manager
Worked on LIPOSYN 10% at Abbott? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.